Related Experiment Videos
[Oral anticoagulation in elderly people]
1Service de gériatrie et readaptation gériatrique Département de médecine CHUV, 101 I Lausanne. stephane.rochat@chuv.ch
Insights
Anticoagulant therapy for elderly atrial fibrillation patients involves balancing stroke prevention against bleeding risks. Guidelines recommend treatment for those over 75, and consider it for those 65-75 with risk factors.
Area of Science:
- Geriatric Medicine
- Cardiology
- Pharmacology
Context:
- Oral anticoagulation in elderly patients with atrial fibrillation presents unique challenges.
- Treatment decisions necessitate a careful balance between preventing ischemic stroke and managing major hemorrhage risks, including intracranial bleeding.
Purpose:
- To outline the complexities of initiating oral anticoagulation in elderly patients diagnosed with atrial fibrillation.
- To emphasize the importance of integrating patient preferences into the shared decision-making process for anticoagulant therapy.
Summary:
- Current guidelines advocate for anticoagulation in atrial fibrillation patients aged 75 and older, provided no contraindications exist.
- Anticoagulation is also recommended for patients aged 65 to 75, particularly those with cardiovascular risk factors.
- Individual patient characteristics and preferences are crucial for informed treatment decisions.
Impact:
- Optimizing anticoagulant therapy in the elderly can reduce stroke incidence while minimizing bleeding complications.
- This approach supports personalized medicine and adherence to treatment guidelines in geriatric cardiology.
- Facilitates informed patient-doctor discussions regarding the benefits and risks of anticoagulation.
Abstract:
Oral anticoagulation in elderly people is a complex problem. The decision to initiate anticoagulant therapy in a patient with atrial fibrillation require to balance potential benefits (decreased risk of ischemic stroke) and risks (major hemorrhage, in particular intracranial), in the context of each patient's specific characteristics. Once the patient has been informed, his/her preferences must be integrated into the treatment decision-making process. Current guidelines recommend anticoagulation in all patients aged 75 years and more with atrial fibrillation who do not have counterindications to this treatment. Patients aged 65 to 75 years should also receive an anticoagulation, especially those with cardio-vascular risk factors.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmacodynamics in Geriatric Patients: Effects of Age
Venous Thrombosis IV: Nursing Management
Drug Dosing: Geriatric Patients